Loading viewer...
investor_presentation
Format: PDF investor_presentation
6 February 2018 Q4 2017 results and market update
Q4 2017 results and market update Disclaimer
All statements in this presentation other than statements of historical fact are
forward -looking statements, which are subject to a number of risks, uncertainties,
and assumptions that are difficult to predict and are based upon assumptions as
to future events that may not prove accurate. Certain such forward -looking
statements can be identified by the use of forward -looking terminology such as
“believe”, “may”, “will”, “should”, “would be”, “expect” or “anticipate” or similar
expressions, or the negative thereof, or other variations thereof, or comparable
terminology, or by discussions of strategy, plans or intentions. Should one or
more of these risks or uncertainties materialise, or should underlying
assumptions prove incorrect, actual results may vary materially from those
described in this presentation as anticipated, believed or expected. Prosafe does
not intend, and does not assume any obligation to update any industry
information or forward -looking statements set forth in this presentation to reflect
subsequent events or circumstances.
2 Q4 2017 Highlights
Good operating performance
Utilisation of 36.1 per cent in the quarter (43 per
Operating revenues at USD 76.7 mill.
Cash flow from operations at USD 44.2 mill.
Delivering on cost and capex reductions. Focus on
continuous improvement remains
Business development presence established in
Positive macro indicators
Foresee gradual pick -up in accommodation
Business & Operations
(Unaudited figures in USD million) Q4 17 Q3 17 Q4 16 2017 2016
Operating revenues 76.7 68.9 125.8 283.0 474.0
Operating expenses (36.6) (41.3) (47.8) (160.1) (220.8)
EBITDA 40.1 27.6 78.0 122.9 253.2
Preview truncated — download the full document for the complete content.
investor_presentation
23 Pages
Brainstorm Cell Therapeutics BCLI Clinical Stage Biotech
investor_presentationinvestor_presentation
29 Pages
Brainstorm Cell Therapeutics
investor_presentation
Cengage
investor_presentation
Urban Air Mobility